Alkermes plans to move ALKS 8700, a novel monomethyl fumarate (MMF) molecule and a competitor for Biogen Idec's successful oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), into pivotal studies following a large, placebo-controlled Phase I clinical trial.
ALKS 8700 showed less variability and improved gastrointestinal tolerability compared with Tecfidera, according to top-line results from the trial, so...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

